NASDAQ:INVAInnoviva Stock Price, Forecast & News

$14.16

-0.55 (-3.74 %)

(As of 05/26/2020 04:00 PM ET)

Add

Compare

Today's Range

$14.09

Now: $14.16▼

$14.88

50-Day Range

$11.55

MA: $13.37▼

$14.46

52-Week Range

$7.58

Now: $14.16▼

$15.35

Volume56,057 shs

Average Volume798,470 shs

Market Capitalization$1.43 billion

P/E Ratio8.28

Dividend YieldN/A

Beta1.05

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Brisbane, California.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Innoviva.

2.2 Community Rank

Outperform Votes
Innoviva has received 284 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Innoviva has received 371 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Innoviva has received 56.64% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote “Outperform” if you believe INVA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Innoviva does not currently pay a dividend.
Dividend Growth
Innoviva does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Innoviva insiders have bought more of their company's stock than they have sold. Specifically, they have bought $22,149,687.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.32% of the stock of Innoviva is held by insiders.
Percentage Held by Institutions
72.95% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Innoviva are expected to decrease by -32.20% in the coming year, from $1.77 to $1.20 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Innoviva is 8.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 13.95.
Price to Earnings Ratio vs. Sector
The P/E ratio of Innoviva is 8.28, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.08.
Price to Book Value per Share Ratio
Innoviva has a P/B Ratio of 4.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.49 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:INVA

Previous SymbolNASDAQ:THRX

CUSIP88338T10

CIK1080014

Webwww.inva.com

Phone650-238-9600

Debt

Debt-to-Equity Ratio0.93

Current Ratio166.87

Quick Ratio166.87

Price-To-Earnings

Trailing P/E Ratio8.28

Forward P/E Ratio8.00

P/E GrowthN/A

Sales & Book Value

Annual Sales$261.02 million

Price / Sales5.50

Cash Flow$1.71 per share

Price / Cash Flow8.30

Book Value$3.38 per share

Price / Book4.19

Profitability

EPS (Most Recent Fiscal Year)$1.43

Net Income$157.29 million

Net Margins66.50%

Return on Equity59.11%

Return on Assets26.69%

Miscellaneous

Employees6

Outstanding Shares101,320,000

Market Cap$1.43 billion

Next Earnings Date7/22/2020 (Estimated)

OptionableOptionable

Receive INVA News and Ratings via Email

Sign-up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter.

Innoviva (NASDAQ:INVA) Frequently Asked Questions

How has Innoviva's stock been impacted by COVID-19 (Coronavirus)?

Innoviva's stock was trading at $12.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INVA shares have increased by 17.6% and is now trading at $14.16. View which stocks have been most impacted by Coronavirus.

When is Innoviva's next earnings date?

Innoviva is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Innoviva.

How were Innoviva's earnings last quarter?

Innoviva Inc (NASDAQ:INVA) announced its earnings results on Wednesday, April, 29th. The biotechnology company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.36 by $0.23. The biotechnology company had revenue of $78.68 million for the quarter. Innoviva had a net margin of 66.50% and a return on equity of 59.11%. View Innoviva's earnings history.

Has Innoviva been receiving favorable news coverage?

News coverage about INVA stock has trended extremely negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Innoviva earned a news impact score of -5.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutInnoviva.

Who are some of Innoviva's key competitors?

Some companies that are related to Innoviva include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Exelixis (EXEL), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Micron Technology (MU), Pfizer (PFE), ImmunoGen (IMGN), Nektar Therapeutics (NKTR), Occidental Petroleum (OXY) and Progenics Pharmaceuticals (PGNX).

Who are Innoviva's key executives?

Innoviva's management team includes the following people:

Mr. Geoffrey Hulme, Interim Principal Exec. Officer (Age 52)
Ms. Marianne Zhen CPA, Chief Accounting Officer (Age 50)
Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
Dr. Kevin Kwok, Head of Talent Acquisition & Strategy

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Who are Innoviva's major shareholders?

Innoviva's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.05%), State Street Corp (2.17%), First Eagle Investment Management LLC (1.73%), Invesco Ltd. (1.48%), Geode Capital Management LLC (0.99%) and Atom Investors LP (0.90%). Company insiders that own Innoviva stock include Geoffrey Hulme, George Bickerstaff, Innoviva, Inc, Marianne Zhen and Theodore J Jr Witek. View institutional ownership trends for Innoviva.

Which institutional investors are selling Innoviva stock?

INVA stock was sold by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Invesco Ltd., BlackRock Inc., Chicago Equity Partners LLC, James Investment Research Inc., Wells Fargo & Company MN, Connor Clark & Lunn Investment Management Ltd., and Deutsche Bank AG. View insider buying and selling activity for Innoviva.

Which institutional investors are buying Innoviva stock?

INVA stock was purchased by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, SG Americas Securities LLC, Robeco Institutional Asset Management B.V., Acadian Asset Management LLC, Atom Investors LP, State Street Corp, Martingale Asset Management L P, and Eaton Vance Management. Company insiders that have bought Innoviva stock in the last two years include Geoffrey Hulme, George Bickerstaff, and Innoviva, Inc. View insider buying and selling activity for Innoviva.

How do I buy shares of Innoviva?

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $14.16.

How big of a company is Innoviva?

Innoviva has a market capitalization of $1.43 billion and generates $261.02 million in revenue each year. The biotechnology company earns $157.29 million in net income (profit) each year or $1.43 on an earnings per share basis. Innoviva employs 6 workers across the globe.

What is Innoviva's official website?

The official website for Innoviva is www.inva.com.

How can I contact Innoviva?

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff